本文選題：宮頸癌 + 中晚期�。� 參考：《山東醫(yī)藥》2017年06期

【摘要】：目的觀察紫杉醇聯(lián)合卡鉑化療同步放療治療中晚期宮頸癌患者的臨床療效。方法將52例中晚期宮頸癌患者隨機分為兩組各26例,觀察組給予紫杉醇聯(lián)合卡鉑化療同步放療,對照組給予單純放療。治療前后檢測兩組血清鱗狀細胞癌相關(guān)抗原(SCCAg)、細胞角蛋白19片段(CYFRA21-1)水平,治療后3~6個月按照WHO實體瘤療效標(biāo)準(zhǔn)評價近期療效,記錄治療期間的不良反應(yīng)。結(jié)果兩組治療后血清SCCAg、CYFRA21-1水平均低于治療前(P均0.05),觀察組治療后SCCAg、CYFRA21-1水平低于對照組(P均0.05);觀察組治療總有效率為80.77%,高于對照組的46.15%(P0.05);觀察組不良反應(yīng)率為34.62%,低于對照組的76.92%(P0.05)。結(jié)論中晚期宮頸癌患者采用紫杉醇聯(lián)合卡鉑化療同步放療的近期療效較單純放療更為顯著,且不良反應(yīng)少。
[Abstract]:Objective to observe the clinical effect of paclitaxel combined with carboplatin chemotherapy in the treatment of advanced cervical cancer. Methods 52 patients with advanced cervical cancer were randomly divided into two groups: the observation group received paclitaxel combined with carboplatin chemotherapy and the control group received radiotherapy alone. The serum levels of SCCAg and CYFRA21-1 were measured before and after treatment. The short-term efficacy of SCCAg and CYFRA21-1 were evaluated 3 ~ 6 months after treatment and adverse reactions were recorded according to WHO criteria. Results after treatment, the levels of serum SCCAgfRA21-1 in both groups were lower than those before treatment (P 0.05), and the levels of SCCAgCYFRA21-1 in the observation group were lower than those in the control group (P 0.05), the total effective rate of the observation group was 80.77, which was higher than 46.15% of the control group (P0.05), the adverse reaction rate of the observation group was 34.62%, lower than that of the control group (76.92%) (P0.05). Conclusion the short-term efficacy of paclitaxel combined with carboplatin chemotherapy in patients with advanced cervical cancer is more significant than that of radiotherapy alone, and the adverse reactions are less.
【作者單位】： 承德市中心醫(yī)院;
【分類號】：R737.33

【參考文獻】

相關(guān)期刊論文 前10條

1 余杰;王e，

本文編號：2058607